Baylor Opens New Immunotherapy Clinical Trial for Mesothelioma

The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,” thoracic surgeon and principal investigator Dr. Bryan Burt told The Mesothelioma Center at Asbestos.com. “You don’t know what the results will be until you try it, but in preclinical studies, there was a very striking response.” The impressive preclinical data is expected to be published later this summer. Burt is part of the Mesothelioma Treatment Program and the Dan L. Duncan Comprehensive Cancer Center at Baylor. He worked alongside legendary mesothelioma specialist Dr. David Sugarbaker, who helped build the Lung Institute before his death in 2018. As a surgeon, Burt understands the lack of effective treatment options available today for patients not eligible for surgery. “I don’t think anyone would argue that the survival benefits, the benefit of systemic therapy for mesothelioma patients, is suboptimal,” Burt sai...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Pioneering pulmonologists Dr. Steven Albelda and Dr. Daniel Sterman have worked for more than 20 years on developing gene therapy to effectively combat pleural mesothelioma cancer. The payoff may have finally arrived. Albelda and Sterman’s long-awaited, phase III clinical trial will open this month to evaluate the efficacy of TR002, a novel gene therapy drug, when used in combination with celecoxib and gemcitabine. TR002, a form of immunotherapy, is a genetically engineered adenovirus that triggers the anti-tumor effects of interferon, a naturally occurring protein that destroys cancer cells. “The hope is, if i...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Overall our data identify virotherapy, based on the use of dl922-947, as a new possible therapeutic strategy against MPM, which could be used alone, in combination with standard chemotherapy drugs, as shown here, or other approaches also aimed at enhancing the antitumoral immune response elicited by the virus.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
A long-awaited phase III clinical trial of a novel gene therapy could change malignant pleural mesothelioma treatment in the future. The trial, which will include almost 50 locations around the world, opens this month for mesothelioma patients whose standard treatment has stopped working. The gene therapy drug, called TR002, is also a form of immunotherapy. It will be used in combination with gemcitabine chemotherapy in a second-line setting. “We can’t predict what the outcome will be, but we’re very excited about the potential of this treatment, and the fact there may be another drug in the armamentarium...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I Abstract The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attrib...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Adenoviruses | Asbestosis | Baylor College of Medicine | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Environmental Health | Immunotherapy | Mesothelioma | Palliative | Study | Toxicology